Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Single Mutation Linked to Fatty Disorders of Liver and Skin

By LabMedica International staff writers
Posted on 05 Aug 2019
The common liver disorder non-alcoholic fatty liver disease (NAFLD) has been found to share a genetic linkage with Chanarin-Dorfman syndrome, a rare skin condition.

NAFLD, which affects more than one-third of the world’s population, is characterized by excessive fat build-up in the liver due to causes other than alcohol use. There are two types of NAFLD: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Non-alcoholic fatty liver usually does not progress to liver damage or NASH. NASH includes both a fatty liver and liver inflammation. It may lead to complications such as cirrhosis, liver cancer, liver failure, or cardiovascular disease. NAFLD displays a strong genetic component, and inherited forms of have been suspected. However, the molecular mechanisms of hereditary NAFLD have not been described.

Investigators at Thomas Jefferson University (Philadelphia, PA, USA) identified a gene, that when mutated, causes NAFLD. This finding was made while the investigators were studying Chanarin-Dorfman syndrome, a severe but rare skin disorder, in several families from Iran. Sufferers of Chanarin-Dorfman syndrome develop dry, reddish, and scaly skin shortly after birth and later on in life acquire abnormally large and fatty livers.

The investigator performed whole-exome or targeted next-generation sequencing on patients from six families who demonstrated autosomal dominant NAFLD. From their results, the investigators described a heritable form of NAFLD and/or dyslipidemia due to monoallelic ABHD5 (abhydrolase domain containing 5) mutations, with complete clinical expression after the fourth decade of life. Mutations in the ABHD5 gene have been associated with Chanarin-Dorfman syndrome, a triglyceride storage disease with impaired long-chain fatty acid oxidation.

The results obtained during the present study came from seven unrelated multiplex families encompassing 39 affected individuals. The prevalence of ABHD5-associated NAFLD was estimated to be one in 1,137 individuals in a normal population.

“Studying a rare, heritable disease such as Chanarin-Dorfman syndrome, can be very helpful in identifying conditions which are much more prevalent, like in the case of non-alcoholic fatty liver disease,” said senior author Dr. Jouni Uitto, professor of dermatology and cutaneous biology at Thomas Jefferson University. “It turns out that if you have one mutated copy of the ABHD5 gene you get the liver disease only, but if you have mutations in both copies then you get the liver disease plus Chanarin-Dorfman syndrome.”

“The link between non-alcoholic fatty liver disease and scaly skin diseases such as Chanarin-Dorfman syndrome highlights the importance of regulated lipid metabolism in skin physiology,” said Dr. Uitto. “In fact, there are several heritable disorders manifesting with dry and scaly skin associated with mutations in genes like ABHD5 that are involved in lipid metabolism. Identification of such genes and specific mutations now form the basis for ongoing studies attempting to develop treatment for these often devastating skin disorders.”

The study was published in the August 2019 issue of the Journal of Hepatology.

Related Links:
Thomas Jefferson University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.